Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 5281 AL 5295

Memantine-associated renal impairment in a patient with Alzheimer's disease

Horikawa N, Yamada H, Uchimura N.

Psychiatry Clin Neurosci. 2013 Feb;67(2):126. doi: 10.1111/pcn.12020.

Role of statins in Alzheimer's disease: a retrospective meta-analysis for commonly investigated clinical parameters in RCTs

Pandey RD, Gupta PP, Jha D, Kumar S.

Int J Neurosci. 2013 Aug;123(8):521-5. doi: 10.3109/00207454.2013.778846. Epub 2013 Apr 9.

[Speech and communication: "what do you want from me?"]

Werner S.

Pflege Z. 2013 Feb;66(2):122-3.

Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

Jang H, Connelly L, Arce FT, Ramachandran S, Lal R, Kagan BL, Nussinov R.

Phys Chem Chem Phys. 2013 Jun 21;15(23):8868-77. doi: 10.1039/c3cp00017f. Epub 2013 Feb 28.

Advances with RNA interference in Alzheimer's disease research

Chen S, Ge X, Chen Y, Lv N, Liu Z, Yuan W.

Drug Des Devel Ther. 2013;7:117-25. doi: 10.2147/DDDT.S40229. Epub 2013 Feb 22.

High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines

Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P.

CNS Neurosci Ther. 2013 May;19(5):294-301. doi: 10.1111/cns.12076. Epub 2013 Mar 6.

Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease

Romero A, Cacabelos R, Oset-Gasque MJ, Samadi A, Marco-Contelles J.

Bioorg Med Chem Lett. 2013 Apr 1;23(7):1916-22. doi: 10.1016/j.bmcl.2013.02.017. Epub 2013 Feb 16.

Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease

Yuan J, Venkatraman S, Zheng Y, McKeever BM, Dillard LW, Singh SB.

J Med Chem. 2013 Jun 13;56(11):4156-80. doi: 10.1021/jm301659n. Epub 2013 Apr 5.

A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease

Patil PO, Bari SB, Firke SD, Deshmukh PK, Donda ST, Patil DA.

Bioorg Med Chem. 2013 May 1;21(9):2434-50. doi: 10.1016/j.bmc.2013.02.017. Epub 2013 Feb 27.

The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation

Nathan PJ, Boardley R, Scott N, Berges A, Maruff P, Sivananthan T, Upton N, Lowy MT, Nestor PJ, Lai R.

Curr Alzheimer Res. 2013 Mar;10(3):240-51. doi: 10.2174/1567205011310030003.

CD4 T cells in immunity and immunotherapy of Alzheimer's disease

Monsonego A, Nemirovsky A, Harpaz I.

Immunology. 2013 Aug;139(4):438-46. doi: 10.1111/imm.12103.

Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies

Rosenmann H.

Curr Alzheimer Res. 2013 Mar;10(3):217-28. doi: 10.2174/1567205011310030001.

Liver X receptors: emerging therapeutic targets for Alzheimer's disease

Sodhi RK, Singh N.

Pharmacol Res. 2013 Jun;72:45-51. doi: 10.1016/j.phrs.2013.03.008. Epub 2013 Mar 28.

Alzheimer disease pharmacologic treatment and treatment research

Schneider LS.

Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):339-57. doi: 10.1212/01.CON.0000429180.60095.d0.

Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease

Adwan L, Zawia NH.

Pharmacol Ther. 2013 Jul;139(1):41-50. doi: 10.1016/j.pharmthera.2013.03.010. Epub 2013 Apr 3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias